Biogen Inc. has reached an agreement to acquire Apellis Pharmaceuticals, Inc. for approximately $5.6 billion. The biotechnology company announced the deal on Tuesday, confirming that the transaction will be conducted entirely in cash.

A test tube stands before a Biogen logo in an illustrative photo taken on December 1, 2021. REUTERS/Dado Ruvic/Illustration